ABVC BioPharma, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $296.0K | $509.6K | $152.4K | $969.8K | $355.8K | $483.0K | $701.7K |
| Cost of Revenue | — | — | $763 | $302.0K | $286.4K | $5.1K | $18.7K | $20.1K |
| Gross Profit | — | — | $508.8K | $-149.6K | $683.4K | $350.7K | $464.3K | $681.6K |
| Gross Margin | — | — | 99.9% | -98.1% | 70.5% | 98.6% | 96.1% | 97.1% |
| Operating Expenses | ||||||||
| Research & Development | — | $121.1K | $179.3K | $1.1M | $2.7M | $1.0M | $549.7K | $1.0M |
| SG&A Expense | — | $2.9M | $2.3M | $5.4M | $6.1M | $5.7M | $4.3M | $3.1M |
| Operating Income | — | $-7.2M | $-4.7M | $-6.8M | $-15.1M | $-11.7M | $-8.5M | $-3.5M |
| Operating Margin | — | -2,416.0% | -923.3% | -4,439.2% | -1,558.5% | -3,290.1% | -1,760.9% | -492.9% |
| Interest Expense | — | $5.5K | $646 | $1.3M | $294.0K | $227.2K | $405.0K | $482.0K |
| Pretax Income | — | $-8.4M | $-5.4M | $-8.0M | $-15.5M | $-11.2M | $-10.8M | $-4.0M |
| Income Tax Expense | — | $24.2K | $-110.5K | $256.0K | $797.8K | $825.0K | $-220.4K | $-77.0K |
| Net Income | — | $-7.9M | $-4.9M | $-7.8M | $-16.4M | $-12.8M | $-10.6M | $-3.9M |
| Net Margin | — | -2,671.8% | -962.1% | -5,109.3% | -1,693.5% | -3,608.5% | -2,193.1% | -560.5% |
| EPS (Basic) | — | $-0.39 | $-0.42 | $-0.60 | $-1.73 | $-0.17 | $-0.17 | $-0.07 |
| EPS (Diluted) | — | $-0.39 | $-0.42 | $-0.60 | $-1.73 | $-0.17 | $-0.17 | $-0.07 |
| Shares Outstanding (Basic) | 25.4M | 20.1M | 11.7M | 13.0M | 9.5M | 75.2M | 59.1M | 58.4M |
| Shares Outstanding (Diluted) | 25.4M | 20.1M | 11.7M | 13.0M | 9.5M | 75.2M | 59.1M | 58.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |